The development of a drug requires on average more than two billion dollars and can take up to 10-15 years. This is why drug repurposing was considered a valuable strategy to deal with the pandemic caused by SARS-CoV-2 in a reasonable time. In addition, computational discovery of repurposed drugs helps avoid costly trial-and-error experiments, which require cell cultures, biochemical screening, and living systems. Thus, baricitinib (rheumatoid arthritis drug) was proposed, using artificial intelligence techniques, as a repurposed drug and was subsequently approved as an emergency treatment by the FDA (US Food and Drug Administration) for the treatment of COVID-19 in combination with redemsivir. Other antivirals already marketed such as favipiravir and EIDD2801 show mixed evidence, while drugs such as lopinavir, ritonavir, hydroxychloroquine and chloroquine eventually proved ineffective. Currently, the clinical treatment of COVID-19 is mainly symptomatic, using anti-inflammatories such as dexamethasone or cytosine inhibitors, combined with antibiotics to treat secondary infections. There is therefore an urgent need to develop specific antiviral therapies against SARS-CoV-2.